A Randomized, Double-Blind, Placebo-Controlled, Multicentre, Phase II Study of Oral Lapatinib in combination with Concurrent Radiotherapy and Cisplatin versus Radiotherapy and Cisplatin alone, in Subjects with Stage III and IVA,B Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Latest Information Update: 05 Sep 2023
Price :
$35 *
At a glance
- Drugs Lapatinib (Primary) ; Cisplatin
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 30 May 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 10 May 2019 This trial has been completed in Netherlands.
- 01 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.